Omeris

Omeros is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing small-molecule and antibody therapeutics for large-market as well as orphan indications. The company's primary development focus is on its complement-targeted pipeline, specifically narsoplimab, a MASP-2 inhibitor targeting various thrombotic microangiopathies and kidney diseases. Omeros also leverages a proprietary G protein-coupled receptor (GPCR) platform to identify first-in-class drugs for CNS disorders and oncology. While the company previously commercialized Omidria for use in intraocular surgery, it has since divested the product to focus on its late-stage clinical pipeline.